Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...

Stifel Nicolaus analyst Mathew Blackman reiterated a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

Canaccord analyst William Plovanic raised the firm’s price target on DexCom (DXCM) to $103 from $99 and keeps a Buy rating on the shares. The ...

Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2024 results topping the market’s revenue expectations, with sales ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...

The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating incomes. Despite these mixed results, DexCom's revenue trajectory indicates ...